News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
512,099 Results
Type
Article (11698)
Company Profile (142)
Press Release (500258)
Multimedia
Podcasts (14)
Webinars (7)
Section
Business (170753)
Career Advice (581)
Deals (26263)
Drug Delivery (19)
Drug Development (60767)
Employer Resources (20)
FDA (11139)
Job Trends (9512)
News (251925)
Policy (19683)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (663)
Accelerated approval (36)
ADA (26)
Adcomms (4)
Allergies (125)
Alliances (34094)
ALS (135)
Alzheimer's disease (1103)
Antibody-drug conjugate (ADC) (307)
Approvals (11875)
Artificial intelligence (355)
ASCO (198)
Autoimmune disease (249)
Automation (33)
Bankruptcy (265)
Best Places to Work (7628)
BIO (40)
Biologics (2)
BIOSECURE Act (1)
Biosimilars (143)
BioSpace Insights (20)
Biotechnology (89)
Bladder cancer (166)
Brain cancer (41)
Breast cancer (566)
Cancer (4234)
Cardiovascular disease (339)
Career advice (500)
Career pathing (44)
CAR-T (209)
CDC (1)
Celiac Disease (1)
Cell therapy (532)
Cervical cancer (35)
Clinical research (55641)
Collaboration (1318)
Commercialization (4)
Company closure (3)
Compensation (1486)
Complete response letters (41)
COVID-19 (946)
CRISPR (68)
C-suite (781)
Cystic fibrosis (92)
Data (6692)
Decentralized trials (1)
Denatured (6)
Depression (122)
Dermatology (75)
Diabetes (457)
Diagnostics (4309)
Digital health (40)
Diversity (3)
Diversity, equity & inclusion (8)
Drug discovery (171)
Drug pricing (16)
Drug shortages (8)
Duchenne muscular dystrophy (183)
Earnings (74992)
Editorial (8)
Employer branding (2)
Employer resources (25)
Events (91341)
Executive appointments (727)
FDA (14118)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (19)
Frontotemporal dementia (23)
Funding (1033)
Gene editing (137)
Generative AI (13)
Gene therapy (344)
GLP-1 (542)
Government (1252)
Grass and pollen (3)
Guidances (305)
Healthcare (10128)
Hematology (107)
HIV (60)
Huntington's disease (29)
IgA nephropathy (94)
Immunology and inflammation (146)
Immuno-oncology (66)
Indications (186)
Infectious disease (1160)
Inflammatory bowel disease (154)
Inflation Reduction Act (4)
Influenza (86)
Intellectual property (266)
Interviews (87)
IPO (12640)
IRA (3)
Job creations (2077)
Job search strategy (417)
JPM (4)
Kidney cancer (22)
Labor market (101)
Layoffs (221)
Leadership (20)
Legal (5468)
Licensing (10)
Liver cancer (50)
Longevity (18)
Lung cancer (602)
Lymphoma (308)
Machine learning (29)
Management (7)
Manufacturing (590)
Marketing (10)
MASH (152)
Medical device (8970)
Medtech (9123)
Mergers & acquisitions (14695)
Metabolic disorders (1028)
mRNA (66)
Multiple sclerosis (130)
NASH (15)
Neurodegenerative disease (263)
Neuropsychiatric disorders (57)
Neuroscience (2137)
NextGen: Class of 2026 (3387)
Non-profit (1249)
Now hiring (71)
Obesity (393)
Opinion (40)
Ovarian cancer (179)
Pain (189)
Pancreatic cancer (228)
Parkinson's disease (233)
Partnered (13)
Patents (487)
Patient recruitment (576)
Peanut (48)
People (42457)
Pharmaceutical (30)
Pharmacy benefit managers (10)
Phase 1 (17183)
Phase 2 (24601)
Phase 3 (17741)
Pipeline (8217)
Policy (25)
Postmarket research (1974)
Preclinical (6899)
Press Release (34)
Prostate cancer (231)
Psychedelics (18)
Radiopharmaceuticals (202)
Rare diseases (674)
Real estate (3151)
Recruiting (10)
Regulatory (16517)
Reports (33)
Research institute (837)
Resumes & cover letters (78)
Rett syndrome (43)
RNA editing (9)
RSV (55)
Schizophrenia (135)
Series A (163)
Series B (133)
Service/supplier (5)
Sickle cell disease (75)
Special edition (9)
Spinal muscular atrophy (105)
Sponsored (7)
Startups (2138)
Stomach cancer (3)
Supply chain (57)
Tariffs (3)
The Weekly (8)
Vaccines (368)
Venture capital (33)
Weight loss (221)
Women's health (90)
Worklife (17)
Date
Today (51)
Last 7 days (250)
Last 30 days (1760)
Last 365 days (20767)
2026 (13574)
2025 (20969)
2024 (24751)
2023 (28313)
2022 (36418)
2021 (39178)
2020 (35422)
2019 (25702)
2018 (19203)
2017 (20187)
2016 (19175)
2015 (25554)
2014 (22615)
2013 (18862)
2012 (20952)
2011 (21216)
2010 (20949)
Location
Africa (285)
Alabama (76)
Alaska (2)
Arizona (308)
Arkansas (11)
Asia (20687)
Australia (2609)
California (12606)
Canada (3243)
China (760)
Colorado (497)
Connecticut (444)
Delaware (286)
Europe (30940)
Florida (1853)
Georgia (399)
Hawaii (3)
Idaho (47)
Illinois (791)
India (62)
Indiana (440)
Iowa (17)
Japan (468)
Kansas (106)
Kentucky (35)
Louisiana (38)
Maine (26)
Maryland (1258)
Massachusetts (8292)
Michigan (314)
Minnesota (575)
Mississippi (5)
Missouri (84)
Montana (20)
Nebraska (13)
Nevada (117)
New Hampshire (61)
New Jersey (3066)
New Mexico (14)
New York (2959)
North Carolina (1344)
North Dakota (4)
Northern California (6274)
Ohio (297)
Oklahoma (15)
Oregon (23)
Pennsylvania (2334)
Puerto Rico (20)
Rhode Island (34)
South America (471)
South Carolina (81)
South Dakota (1)
Southern California (5253)
Tennessee (126)
Texas (1991)
United States (41127)
Utah (375)
Vermont (1)
Virginia (171)
Washington D.C. (45)
Washington State (958)
West Virginia (2)
Wisconsin (77)
Wyoming (2)
512,099 Results for "anges mg inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Dr. Reddy’s Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States
August 4, 2026
·
3 min read
Press Releases
Vitruvias Therapeutics, Inc. Issues Nationwide Recall of One Lot of Thyroid Tablets, USP 30 mg Due to Potential Super Potency
August 23, 2026
·
2 min read
Press Releases
Celltrion Expands Omlyclo® Portfolio in Europe with Launch of 300 mg Strength
August 25, 2026
·
4 min read
Press Releases
FDA Approves TYLENOL® with Naproxen, the First and Only Over-the-Counter Fixed-Dose Combination of Acetaminophen (650 mg) and Naproxen Sodium (220 mg)
July 26, 2026
·
7 min read
Press Releases
Vasomune Therapeutics, Inc., and AnGes, Inc., Announce US FDA Clearance of Investigational New Drug (IND) Application For Pegevongitide (AV-001) Treatment in Resuscitation of Severely Burned Patients
March 4, 2026
·
3 min read
Press Releases
Vasomune Therapeutics Inc., and AnGes Inc., Expand the Scope of the Co-Development Agreement to Target Additional Indications
November 26, 2025
·
2 min read
Press Releases
Bermoxel® (Praziquantel 600 mg) Now Available Across All 27 EU Member States Amid Restricted Biltricide® Availability
August 18, 2026
·
1 min read
Venture capital
Ollin parlays Vabysmo beat into $330M raise to test eye disease drug in Phase 3
With positive feedback on a Phase 3 trial design, Ollin Biosciences has collected a $330 million series B to advance its VEGF/Ang2 antibody, which bested Genentech’s therapy in a head-to-head study.
June 24, 2026
·
1 min read
·
Annalee Armstrong
Press Releases
Biocon Announces U.S. Commercial Launch of Yesafili™, a Biosimilar to Regeneron’s Eylea® 2 mg
August 3, 2026
·
6 min read
Press Releases
JW Pharmaceutical Proves Efficacy of Key 6mg Dose of Gout Treatment ‘Epaminurad’ in Multinational Phase 3 Trial
August 13, 2026
·
4 min read
1 of 51,210
Next
